The Psyence™ Group sets the global standard for natural psychedelics.
Informed by nature and guided by science, Psyence is a life science biotechnology company pioneering the use of natural psilocybin to heal psychological trauma and the diagnosable disorders that can result: anxiety, depression, PTSD, stress, grief and bereavement. We have a focus on these conditions in the context of palliative care.
We are focused on the development of psilocybin medical products for research institutions and clinics and will also manufacture regulatory-compliant over the counter psilocybin containing products. We are also developing nutraceutical products for depression, acute anxiety and sleep disorders.
Psyence is listed on the Canadian Stock Exchange (CSE: PSYG) and our diversified business has a global footprint with operations in multiple legal jurisdictions. We operate one of the first federally licensed commercial psilocybin cultivation and production facilities in the world in Southern Africa.
The Psyence™ Group sets the global standard for natural psychedelics.
Informed by nature and guided by science, Psyence is a life science biotechnology company pioneering the use of natural psilocybin to heal psychological trauma and the diagnosable disorders that can result: anxiety, depression, PTSD, stress, grief and bereavement. We have a focus on these conditions in the context of palliative care.
We are focused on the development of psilocybin medical products for research institutions and clinics and will also manufacture regulatory-compliant over the counter psilocybin containing products. We are also developing nutraceutical products for depression, acute anxiety and sleep disorders.
Psyence is listed on the Canadian Stock Exchange (CSE: PSYG) and our diversified business has a global footprint with operations in multiple legal jurisdictions. We operate one of the first federally licensed commercial psilocybin cultivation and production facilities in the world in Southern Africa.
Psyence is pioneering the use of natural psilocybin for the long-term treatment of trauma and its mental health consequences.
Bringing together leaders in the business of medicine and science
Our scientific and medical team, which includes experts in neurology, neuroscience, oncology and drug development, have international expertise in palliative medicine and science. Our global executive team has extensive capital market and business building experience and a track record for creating shareholder value and achieving sustainable growth.
Our News
Hannam & Partners Independent Research Report
Hannam & Partners issued an independent research report on Psyence identifying it as a first mover into the palliative care market supported by natural psilocybin production.
Psyence Group Announces Amendment and Closing of Previously Announced Private Placement
We are pleased to announce, further to the Company’s press release dated December 2, 2021, the amendment and closing of its first tranche of the previously announced non-brokered private placement offering (the “Private Placement”) raising gross process of $1.273 million.
Psyence Taps Another Pharma Exec To Drive Its Clinical Program
Psyence Taps Another Pharma Exec To Drive Its Clinical [...]
Our News
Hannam & Partners Independent Research Report
Hannam & Partners issued an independent research report on Psyence identifying it as a first mover into the palliative care market supported by natural psilocybin production.
Psyence Group Announces Amendment and Closing of Previously Announced Private Placement
We are pleased to announce, further to the Company’s press release dated December 2, 2021, the amendment and closing of its first tranche of the previously announced non-brokered private placement offering (the “Private Placement”) raising gross process of $1.273 million.
Psyence Group Corporate Update
Psyence Group Corporate Update
Our Global Footprint
Our team and operations are located across Toronto, Canada; Washington DC, United States of America; Cape Town, South Africa; Kolojane, Kingdom of Lesotho; Kingston, Jamaica; London United Kingdom; Sydney, Australia and Sao Paulo, Brazil.